Interventional Cardiology, A.O. Fatebenefratelli Milano, Italy.
Catheter Cardiovasc Interv. 2014 Feb 15;83(3):427-35. doi: 10.1002/ccd.25149. Epub 2013 Sep 23.
Drug-coated balloons are a new tool for the treatment of patients with coronary artery disease. The main feature of this technology is a rapid and homogenous transfer of an antiproliferative drug (paclitaxel) to the vessel wall just at the time of balloon inflation, when neointimal proliferation, in response to angioplasty, is the highest. Moreover, drug-coated balloons share adjuntive advantages over stents: the absence of permanent scaffold and polymer, the respect of the original coronary anatomy, and limited inflammatory stimuli, thereby allowing for short-term dual antiplatelet therapy. To this day, a lot of devices are available in the market, with limited scientific data for the vast majority of them. Thus, the Italian scientific society of interventional cardiologists GISE decided to coordinate the efforts of a group of reknown experts on the field, in order to obtain a Position Paper on the correct use of drug-coated balloons in all the settings of coronary artery disease, giving a class of indication to each one, based on the clinical evidence. This Position Paper represents a quick reference for operators, investigators, and manufactures to promote the understanding and the correct use of the drug-coated balloon technology in everyday clinical practice.
药物涂层球囊是一种治疗冠状动脉疾病患者的新工具。该技术的主要特点是在球囊扩张时，将一种抗增殖药物（紫杉醇）迅速且均匀地转移到血管壁上，此时血管内膜增生反应最高。此外，药物涂层球囊与支架相比具有辅助优势：不存在永久性支架和聚合物，保留了原始冠状动脉解剖结构，炎症刺激有限，从而允许短期双联抗血小板治疗。时至今日，市场上有很多种设备，但其中绝大多数的科学数据有限。因此，意大利介入心脏病学家 GISE 科学学会决定协调一组该领域知名专家的努力，以获得一份关于在所有冠状动脉疾病情况下正确使用药物涂层球囊的立场文件，根据临床证据为每种药物涂层球囊指定一个适应证类别。本立场文件为操作者、研究人员和制造商提供了快速参考，以促进在日常临床实践中对药物涂层球囊技术的理解和正确使用。
